+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07510802

Phase 12 Study of Dual-target CAR-NK Cell Therapy for Adults With Advanced or Metastatic HER2-positive and Triple-negative Breast Cancer

Led by Beijing Biotech · Updated on 2026-04-06

60

Participants Needed

1

Research Sites

57 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and initial anti-tumor activity of a new dual-target CAR-NK cell therapy for adults with advanced breast cancer, including HER2-positive and triple-negative breast cancer TNBC. This study is designed in two parts the first identifies a safe dose of the CAR-NK cells, and the second assesses early effectiveness in specific groups based on tumor biomarkers. Tumor samples will be tested to identify the most suitable CAR-NK product targeting HER2, MUC1, or ROR1 antigens, with mesothelin testing in TNBC cases for exploratory purposes. Participants receive a course of lymphodepleting chemotherapy fludarabine and cyclophosphamide before getting an intravenous infusion of the dual-target CAR-NK cell therapy. One infusion is given on Day 0, with an optional second infusion on Day 7 if no severe toxicities occur and the participants condition allows. The therapy is personalized based on tumor antigen expression, with different CAR-NK constructs assigned to participants accordingly. During the study, participants will be monitored for safety, including dose-limiting toxicities within 28 days and overall safety to determine the recommended dose over 56 days. Researchers will also measure tumor response and disease control over 12 months. Participants undergo regular assessments, including tumor imaging and health evaluations, to monitor effects and any side effects of the treatment. The total study participation spans from initial screening through follow-up visits over the course of a year or more.

CONDITIONS

Brief Title

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Research Team

S

shan S Lu, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here